UConn gene discovery moves closer to treating neuromuscular disease, holds promise for weight loss
The challenge of the obesity epidemic is widespread and one that even pediatricians face constantly,” a Connecticut doctor ...
Fat, not muscle: drugmakers in race for next weight-loss breakthrough
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...
Inc26d
These Drugs Could Offset the Side Effects of Weight Loss
Keros’ drug, KER-065, which targets myostatin and activin A proteins, increased lean mass and reduced fat mass in obese mice when given alone and in combination with semaglutide, the active ...
Nature28d
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
Scholar Rock has submitted its anti-myostatin antibody apitegromab for FDA approval, just months after reporting that it hit its primary endpoint in phase III for spinal muscular atrophy (SMA).
Nasdaq6d
Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA to Discuss EL-22 for Muscle Preservation in Obesity Treatment
A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein, BLS-M22, Int. J. Mol. Sci. 2022, 23, 9059.
U.S. News & World Report26d
Fat, Not Muscle: Drugmakers in Race for Next Weight-Loss Breakthrough
Keros Pharma Keros' drug, KER-065, which targets myostatin and activin A proteins, increased lean mass and reduced fat mass in obese mice when given alone and in combination with semaglutide ...